Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome

Polona Novak; Tatjana Zabelina; Christine Wolschke; Francis Ayuk; Maximilian Christopeit; Nicolaus Kröger

doi:10.1016/j.bbmt.2020.07.018

Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome

Standard

Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome. / Novak, Polona; Zabelina, Tatjana; Wolschke, Christine ; Ayuk, Francis ; Christopeit, Maximilian ; Kröger, Nicolaus.

In: BIOL BLOOD MARROW TR, Vol. 26, No. 11, 11.2020, p. 2047-2052.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Novak, P, Zabelina, T, Wolschke, C , Ayuk, F , Christopeit, M & Kröger, N 2020, 'Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome', BIOL BLOOD MARROW TR, vol. 26, no. 11, pp. 2047-2052. https://doi.org/10.1016/j.bbmt.2020.07.018

APA

Novak, P., Zabelina, T., Wolschke, C., Ayuk, F., Christopeit, M., & Kröger, N. (2020). Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome. BIOL BLOOD MARROW TR, 26(11), 2047-2052. https://doi.org/10.1016/j.bbmt.2020.07.018

Vancouver

Novak P, Zabelina T, Wolschke C , Ayuk F , Christopeit M , Kröger N. Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome. BIOL BLOOD MARROW TR. 2020 Nov;26(11):2047-2052. https://doi.org/10.1016/j.bbmt.2020.07.018

Bibtex

@article{58d913276ea341c8a13a8884bbd8df19,

title = "Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome",

abstract = "The indication for allogeneic stem cell transplantation (SCT) in patients with lower-risk myelodysplastic syndrome (MDS) is controversial. Here we report 60 patients with a low risk (n = 32) or intermediate risk (n = 28) classification according to the revised International Prognostic Scoring System (IPSS-R) who underwent allogeneic SCT with a reduced-intensity conditioning (n = 45) or myeloablative conditioning (n = 15) regimen from an HLA-identical sibling (n = 9), a matched unrelated donor (n = 36), or a mismatched unrelated donor (n = 15). The rates of grade II-IV and grade III-IV acute graft-versus-host disease were 32% and 7%, respectively, resulting in a transplantation-related mortality (TRM) of 17% at 3 years. The cumulative incidence of relapse at 5 years was only 7%, resulting in a 5-year disease-free survival of 72% and overall survival (OS) of 79%. Transplantation from a fully matched donor resulted in significantly improved OS at 5 years (91% versus 70%). Allogeneic SCT in lower-risk MDS (IPSS-R low or intermediate risk) from an HLA-matched donor resulted in excellent OS with a low risk of relapse.",

author = "Polona Novak and Tatjana Zabelina and Christine Wolschke and Francis Ayuk and Maximilian Christopeit and Nicolaus Kr{\"o}ger",

year = "2020",

month = nov,

doi = "10.1016/j.bbmt.2020.07.018",

language = "English",

volume = "26",

pages = "2047--2052",

journal = "BIOL BLOOD MARROW TR",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "11",

}

RIS

TY - JOUR

T1 - Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome

AU - Novak, Polona

AU - Zabelina, Tatjana

AU - Wolschke, Christine

AU - Ayuk, Francis

AU - Christopeit, Maximilian

AU - Kröger, Nicolaus

PY - 2020/11

Y1 - 2020/11

N2 - The indication for allogeneic stem cell transplantation (SCT) in patients with lower-risk myelodysplastic syndrome (MDS) is controversial. Here we report 60 patients with a low risk (n = 32) or intermediate risk (n = 28) classification according to the revised International Prognostic Scoring System (IPSS-R) who underwent allogeneic SCT with a reduced-intensity conditioning (n = 45) or myeloablative conditioning (n = 15) regimen from an HLA-identical sibling (n = 9), a matched unrelated donor (n = 36), or a mismatched unrelated donor (n = 15). The rates of grade II-IV and grade III-IV acute graft-versus-host disease were 32% and 7%, respectively, resulting in a transplantation-related mortality (TRM) of 17% at 3 years. The cumulative incidence of relapse at 5 years was only 7%, resulting in a 5-year disease-free survival of 72% and overall survival (OS) of 79%. Transplantation from a fully matched donor resulted in significantly improved OS at 5 years (91% versus 70%). Allogeneic SCT in lower-risk MDS (IPSS-R low or intermediate risk) from an HLA-matched donor resulted in excellent OS with a low risk of relapse.

AB - The indication for allogeneic stem cell transplantation (SCT) in patients with lower-risk myelodysplastic syndrome (MDS) is controversial. Here we report 60 patients with a low risk (n = 32) or intermediate risk (n = 28) classification according to the revised International Prognostic Scoring System (IPSS-R) who underwent allogeneic SCT with a reduced-intensity conditioning (n = 45) or myeloablative conditioning (n = 15) regimen from an HLA-identical sibling (n = 9), a matched unrelated donor (n = 36), or a mismatched unrelated donor (n = 15). The rates of grade II-IV and grade III-IV acute graft-versus-host disease were 32% and 7%, respectively, resulting in a transplantation-related mortality (TRM) of 17% at 3 years. The cumulative incidence of relapse at 5 years was only 7%, resulting in a 5-year disease-free survival of 72% and overall survival (OS) of 79%. Transplantation from a fully matched donor resulted in significantly improved OS at 5 years (91% versus 70%). Allogeneic SCT in lower-risk MDS (IPSS-R low or intermediate risk) from an HLA-matched donor resulted in excellent OS with a low risk of relapse.

U2 - 10.1016/j.bbmt.2020.07.018

DO - 10.1016/j.bbmt.2020.07.018

M3 - SCORING: Journal article

C2 - 32717435

VL - 26

SP - 2047

EP - 2052

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 11

ER -